# Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

> **NCT06456346** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 300 (estimated)

## Conditions studied

- Essential Thrombocythemia

## Interventions

- **DRUG:** Bomedemstat
- **DRUG:** Hydroxyurea
- **DRUG:** Bomedemstat placebo
- **DRUG:** Hydroxyurea placebo

## Key facts

- **NCT ID:** NCT06456346
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-16
- **Primary completion:** 2027-09-28
- **Final completion:** 2028-03-24
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456346, "Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06456346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*